Fintel reports that on April 8, 2025, Goldman Sachs upgraded their outlook for Eli Lilly and (NYSE:LLY) from Neutral to Buy.

We recently published a list of Jim Cramer Nailed These 11 Stock Picks. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim ...

Across Wall Street, 44 publicly traded companies were upgraded Tuesday to an equivalent rating of "buy" or "neutral." ...

Goldman Sachs upgraded Eli Lilly (LLY) to Buy from Neutral with a price target of $888, down from $892, after assuming coverage of the name.

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

An account that goes by the handle "Walter Bloomberg" shared a snippet that reportedly came from National Economic Council ...

The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration’s focus on ...

After CMS excluded a Biden administration proposal for CMS to cover anti-obesity medications proposal from the final contract year 2026 ...

The CMS has opted not to move forward with a plan that would have extended Medicare coverage to obesity drugs for millions of ...

We recently published a list of Starter Stock Portfolio 12 Safe Stocks to Buy. In this article, we are going to take a look ...

What should investors do when stocks are tanking over the short term? Three Motley Fool contributors think they've found great dividend stocks to own for the long term that pay you to wait for better ...

Eli Lilly (NYSE:LLY) has recently announced several developments, including positive Phase 2 results for their siRNA therapy ...